Focal Segmental Glomerulosclerosis

Nephrology·MeSH: Glomerulosclerosis, Focal Segmental

15 drugs in development·8 companies·11 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
praliciguat	Cyclerion Therapeutics, Inc. (CYCN)

Phase 3(5)

Drug	Company
DMX-200	AMICUS THERAPEUTICS, INC. (FOLD)
frexalimab	Sanofi (SNY)
Frexalimab	Sanofi (SNY)
Irbesartan	Travere Therapeutics, Inc. (TVTX)
Rilzabrutinib	Sanofi (SNY)

Phase 2(6)

Drug	Company
brivekimig	Sanofi (SNY)
brivekimig	Sanofi (SNY)
mannac	GH Research PLC (GHRS)
mannac	National Research Corporation Common Stock (Delaware) (NRC)
praliciguat	Akebia Therapeutics, Inc. (AKBA)
sparsentan	Travere Therapeutics, Inc. (TVTX)

Preclinical(1)

Drug	Company
pcs499	Processa Pharmaceuticals, Inc. (PCSA)

BLA Filed(1)

Drug	Company
FILSPARI	Travere Therapeutics, Inc. (TVTX)

Phase 4(1)

Drug	Company
No sparsentan	Travere Therapeutics, Inc. (TVTX)

BioSniper tracks 15 drugs in development for Focal Segmental Glomerulosclerosis across 8 companies.

There are 11 clinical trials targeting Focal Segmental Glomerulosclerosis tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.